

26<sup>th</sup> August, 2025

<p><b>To,</b> <b>Department of Corporate Services</b> <b>BSE Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p><b>Ref.: Scrip Code No. : 540701 (Equity)</b> <b>:975834 and 976560 (Debt)</b></p>	<p><b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p><b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b></p>
--	--

**SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 and 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY’S NARODA UNIT RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA)**

Dear Sir,

With reference to the captioned subject, we would like to inform that the Company’s Naroda facility was successfully inspected by the US FDA between 9<sup>th</sup> June, 2025 to 13<sup>th</sup> June, 2025, which was successfully completed on 12<sup>th</sup> June, 2025. In this regard, the Company has intimated about the same to the stock exchange on 13<sup>th</sup> June, 2025.

Further, in this regard, we are pleased to share that today the Company has received intimation about the Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Thus, the Company’s facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the US FDA.

Kindly take this on your record.

Thanking You,

Yours faithfully,

**For, Dishman Carbogen Amcis Limited**

**Shrima Dave**  
**Company Secretary**